New drug targets Hard-to-Treat cancer mutation in first human trial
NCT ID NCT07023731
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that dose in people with advanced pancreatic cancer. About 159 participants will receive the drug intravenously.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARV-806 (a drug that breaks down a specific mutated protein in cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced cancers with a specific KRAS mutation, especially pancreatic cancer.
What could go wrong
This is the first time ARV-806 is tested in humans, so safety and effectiveness are unknown. The trial is small and early-stage, so results may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGPhoenix, Arizona, 85004, United States
-
Clinical Trial Site
RECRUITINGPhoenix, Arizona, 85054, United States
-
Clinical Trial Site
RECRUITINGNew Haven, Connecticut, 06510, United States
-
Clinical Trial Site
RECRUITINGTampa, Florida, 33612, United States
-
Clinical Trial Site
NOT_YET_RECRUITINGIndianapolis, Indiana, 46250, United States
-
Clinical Trial Site
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10032, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10065, United States
-
Clinical Trial Site
RECRUITINGHuntersville, North Carolina, 28078, United States
-
Clinical Trial Site
RECRUITINGCleveland, Ohio, 44106, United States
-
Clinical Trial Site
RECRUITINGHouston, Texas, 77030-7009, United States
-
Clinical Trial Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Clinical Trial Site
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Clinical Trial Site
RECRUITINGFairfax, Virginia, 22031, United States